DK3033101T3 - Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab - Google Patents
Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab Download PDFInfo
- Publication number
- DK3033101T3 DK3033101T3 DK14835826.0T DK14835826T DK3033101T3 DK 3033101 T3 DK3033101 T3 DK 3033101T3 DK 14835826 T DK14835826 T DK 14835826T DK 3033101 T3 DK3033101 T3 DK 3033101T3
- Authority
- DK
- Denmark
- Prior art keywords
- benralizumab
- ser
- leu
- thr
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Bathtubs, Showers, And Their Attachments (AREA)
Claims (12)
1. Effektiv mængde af benralizumab til anvendelse til behandling af astma, hvor benralizumab administreres til en astmapatient, hvor administrationen reducerer patientens eksacerbationsrate, og hvor benralizumab administreres ved en dosis på 30 mg én gang hver 4. uge i 12 uger og herefter én gang hver 8. uge.
2. Benralizumab til anvendelse ifølge krav 1, hvor astmaen er eosinofil astma.
3. Benralizumab til anvendelse ifølge et hvilket som helst af krav 1 eller 2, hvor patienten har et blodeosinofiltal på mindst 300 celler/μΐ.
4. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor patienten har et forceret ekspiratorisk volumen (FEVi) på mindst 75 % forventet værdi før administration.
5. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor patienten har en score på astmakontrolspørgeskema på mindst 1,5 før administration.
6. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-5, der reducerer den årlige eksacerbationsrate efter administration af antistoffet.
7. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor den årlige eksacerbationsrate reduceres med mindst 35 %, eventuelt med mindst 40 %, eventuelt med mindst 50 %, eventuelt med mindst 60 %.
8. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor patienten anvender højdosis inhalerede kortikosteroider (ICS).
9. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor patienten anvender langtidsvirkende β2-agonister (LABA).
10. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-9, hvor patienten har eksacerbationer i anamnesen, eventuelt hvor eksacerbationerne i anamnesen omfatter mindst to eksacerbationer i løbet af året forud for administrationen af benralizumab, eventuelt hvor eksacerbationerne i anamnesen ikke omfatter mere end seks eksacerbationer i løbet af året forud for administrationen af benralizumab.
11. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor benralizumab administreres parenteralt, eventuelt hvor benralizumab administreres subkutant.
12. Benralizumab til anvendelse ifølge et hvilket som helst af kravene 1-11, hvor benralizumab administreres foruden kortikosteroidterapi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864944P | 2013-08-12 | 2013-08-12 | |
| PCT/US2014/050080 WO2015023504A1 (en) | 2013-08-12 | 2014-08-07 | Methods for reducing exacerbation rates of asthma using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3033101T3 true DK3033101T3 (da) | 2019-04-08 |
Family
ID=52448837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14835826.0T DK3033101T3 (da) | 2013-08-12 | 2014-08-07 | Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9441037B2 (da) |
| EP (1) | EP3033101B1 (da) |
| JP (4) | JP6746495B2 (da) |
| KR (2) | KR20220057637A (da) |
| CN (2) | CN105451760A (da) |
| AU (2) | AU2014306956B2 (da) |
| BR (1) | BR112016002401A8 (da) |
| CA (1) | CA2918105C (da) |
| CY (1) | CY1122132T1 (da) |
| DK (1) | DK3033101T3 (da) |
| ES (1) | ES2716906T3 (da) |
| HK (1) | HK1221644A1 (da) |
| HR (1) | HRP20190405T1 (da) |
| HU (1) | HUE042607T2 (da) |
| LT (1) | LT3033101T (da) |
| ME (1) | ME03348B (da) |
| MX (1) | MX368508B (da) |
| PL (1) | PL3033101T3 (da) |
| PT (1) | PT3033101T (da) |
| RS (1) | RS58404B1 (da) |
| RU (1) | RU2676333C2 (da) |
| SG (2) | SG10202005560UA (da) |
| SI (1) | SI3033101T1 (da) |
| SM (1) | SMT201900163T1 (da) |
| TR (1) | TR201903312T4 (da) |
| WO (1) | WO2015023504A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100152T1 (it) | 2013-08-12 | 2021-05-07 | Astrazeneca Ab | Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab |
| RU2728578C2 (ru) * | 2013-08-12 | 2020-07-30 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
| WO2015057668A1 (en) * | 2013-10-15 | 2015-04-23 | Medimmune, Llc | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| CA2926089C (en) * | 2013-10-24 | 2022-08-30 | Medimmune, Llc | Stable, aqueous antibody formulations |
| ES2866935T3 (es) | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
| US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
| EP3371225A2 (en) | 2015-11-04 | 2018-09-12 | AstraZeneca AB | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| EP3565823B1 (en) | 2017-01-04 | 2024-05-29 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | S-arrestin peptides and therapeutic uses thereof |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7404953B2 (en) | 2000-02-15 | 2008-07-29 | Kyowa Hakko Kogyo Co., Ltd. | Methods using eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| WO2005035583A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Ｉｌ－５受容体に特異的に結合する抗体組成物 |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| MX376656B (es) | 2007-05-14 | 2025-03-07 | Kyowa Kirin Co Ltd | Metodos para reducir niveles de basófilos. |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| AU2010322066A1 (en) * | 2009-11-18 | 2012-06-21 | Medicinova, Inc. | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom |
| RU2578468C2 (ru) | 2010-12-16 | 2016-03-27 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием th2 |
| WO2012158954A1 (en) | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| US20140328839A1 (en) | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| RU2728578C2 (ru) | 2013-08-12 | 2020-07-30 | Астразенека Аб | Способы нормализации симптомов астмы с применением бенрализумаба |
| SMT202100152T1 (it) | 2013-08-12 | 2021-05-07 | Astrazeneca Ab | Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab |
-
2014
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/da active
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Ceased
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active Active
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en not_active Ceased
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 SM SM20190163T patent/SMT201900163T1/it unknown
-
2016
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
-
2019
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108991A patent/JP2024129139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3033101T3 (da) | Fremgangsmåder til reducering af eksacerbationsrater for astma ved anvendelse af benralizumab | |
| AU2020202564A1 (en) | Methods for improving asthma symptoms using benralizumab | |
| CA2917603C (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| RU2840902C2 (ru) | Способы нормализации симптомов астмы с применением бенрализумаба | |
| HK40064505A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| HK40012636A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK1225303B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225300B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40035226A (en) | Methods for reducing exacerbation rates of asthma using benralizumab |